Lexaria Bioscience Corp Stock Today
LEXXW Stock | USD 0.75 0.04 5.63% |
Performance1 of 100
| Odds Of DistressOver 54
|
Lexaria Bioscience is selling for under 0.75 as of the 12th of December 2024; that is 5.63% increase since the beginning of the trading day. The stock's lowest day price was 0.69. Lexaria Bioscience has 54 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of January 2021 | Category Healthcare | Classification Health Care |
Lexaria Bioscience Corp. operates in the drug delivery platform business. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. More on Lexaria Bioscience Corp
Moving together with Lexaria Stock
Moving against Lexaria Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Lexaria Stock Highlights
President Director | John MSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexaria Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexaria Bioscience's financial leverage. It provides some insight into what part of Lexaria Bioscience's total assets is financed by creditors.
|
Lexaria Bioscience Corp (LEXXW) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.79 M. Lexaria Bioscience Corp classifies itself under Biotechnology sector and is part of Health Care industry.
Lexaria Bioscience Corp has accumulated about 1.31 M in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Lexaria Bioscience Probability Of Bankruptcy
Lexaria Bioscience Historical Income Statement
Lexaria Stock Against Markets
Lexaria Bioscience Corporate Management
Christopher Bunka | Chairman CEO | Profile | |
Vanessa Carle | Head Legal | Profile | |
Philip Ainslie | Advisor Consultant | Profile | |
Nelson CPA | Chief Officer | Profile | |
Richard Christopher | Chief Officer | Profile | |
Michael CPA | Chief Officer | Profile |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.